Data presented at the EORTC-NCI-AACR International Symposium Demonstrate High Sensitivity and Strong Quantitative Performance with Trovagene's Precision Cancer Monitoring Platform

Stifel 2014 Healthcare Conference and Cannacord Genuity Medical Technologies and Diagnostics Forum

Prospective blinded study demonstrates ability to accurately determine mutational status and monitor response to BRAF inhibitor therapy from urinary cell-free DNA

BIO Investor Forum to be held October 7-8 in San Francisco, California

BRAF V600E assay improves determination of mutational status and allows monitoring of treatment response

Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients

Data from Urinary Cell-free DNA Presented at Next Generation Dx Summit

Strengthens balance sheet to fund clinical programs, commercialization efforts, and continued expansion of oncogene mutation portfolio for cancer monitoring

Company continues to engage leading cancer treatment centers to investigate non-invasive methods of cancer mutation detection in order to advance patient care

Clinical Study Results Published in 2014 ASCO Annual Meeting Proceedings, a Journal of Clinical Oncology

Non-invasive detection and monitoring of actionable oncogene mutation in Erdheim-Chester disease serves as a model case for clinical utility

Data demonstrate utility of non-invasive testing using urinary cell-free DNA to determine oncogene mutation status for therapy selection

Study results show correlation between mutational status and treatment response, as well as concordance between BRAF V600E mutation assay and tissue biopsy at baseline

Partnership Seeks To Establish Clinical and Health Economic Benefits of Trovagene's Urine-Based Cell-Free Molecular Diagnostics for Potential Adoption in Cancer Management Strategies

Expanding Cancer Monitoring Platform with Additional Oncogene Mutation Assays, Building Clinical Evidence to Facilitate Broad Adoption

Company leveraging the scalability of its proprietary platform and next generation sequencing to introduce a full line of multiplexed urine-based oncogene mutation assays with superb sensitivity

2014 BIO CEO & Investor Conference and Leerink Global Healthcare Conference

First clinical results presented on novel molecular diagnostics to optimize cancer treatment; Ends quarter with approximately $28 million in cash

Initial data from ongoing clinical study presented by MD Anderson Cancer Center and Trovagene at AACR-NCI-EORTC International Conferences highlights promise of urine-based, cell-free diagnostics

Findings from studies investigating clinical validity of non-invasive cancer-mutation monitoring platform will be shared for first time at AACR-NCI-EORTC conference on October 21, 2013

Cell-free DNA assay transferred to CLIA laboratory for patient testing

Study to investigate Trovagene's non-invasive cancer monitoring technology using cell-free DNA from urine samples

Rodman & Renshaw 15th Annual Global Healthcare Conference and Stifel Healthcare Conference 2013

Digital PCR system adoption helps create ultra-sensitive cell-free DNA assay

Patent covers methods of detecting cell-free microRNA in urine and blood

Trovagene develops ultra-sensitive cell-free DNA assay

Presentation scheduled on June 27, 2013 at 9:20 a.m. ET in New York

Presentation scheduled on June 6, 2013 at 3:00 p.m. ET in New York

New, non-invasive molecular diagnostic test is easy, fast, and accurate

Presentation scheduled on March 19, 2013 at 12:00 p.m. PT at the Ritz-Carlton Laguna Nigel, in Dana Point, CA

Presentation scheduled on February 13, 2013 at 9:00 a.m. ET at the Waldorf Astoria in New York City

Study with MD Anderson will compare detection of BRAF mutations in urine to biopsy samples, and monitor therapeutic response, outcomes

Renowned molecular geneticist strengthens Trovagene's scientific expertise

COMPANY CONTINUES TO DEVELOP PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE

Issuance of First US NPM1 Patent Triggers Milestone Payment

COMPANY CONTINUES TO EXPAND PROGRAMS IN CANCER AND INFECTIOUS DISEASE DETECTION IN URINE

Study will compare detection of KRAS mutations in urine to their detection in biopsy samples

Internationally recognized cancer researcher and physician strengthens Trovagene's scientific expertise in cancer genetics

Company plans to establish comprehensive panel of assays to detect oncogene mutations in the urine of cancer patients

- Pharmaceutical and diagnostic sales and marketing executive will provide leadership to accelerate commercial programs -

License Complements Franchise of the Company's Proprietary Tumor Marker Assets in Hematological Cancers